2.11
2.11 (0%)
As of Feb 14, 2025
Intensity Therapeutics, Inc [INTS]
Source:
Company Overview
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction leading to anti-cancer immune activation. Our new approach involves the direct injection into tumors of a unique product created from our DfuseRxSM discovery platform.
| Country | United States |
| Headquarters | shelton, connecticut |
| Phone Number | ( 203 ) 221-7381 |
| Industry | manufacturing |
| CEO | Lewis H. Bender |
| Website | www.intensitytherapeutics.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-0 |
| Net Income | $-0 |
| Net Cash | $-6 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -0.2% |
| Profit as % of Stockholder Equity | -0.6% |
Management Effectiveness
| Return on Equity | -0.6% |
| Return on Assets | -0.3% |
| Turnover Ratio | |
| EBITA | $-0 |
Balance Sheet and Cash Flow Measures
| Total Assets | $4.8 |
| Total Liabilities | $1.9 |
| Operating Cash Flow | $-15.2 |
| Investing Cash Flow | $6.4 |
| Financing Cash Flow | $2.9 |
